However, only 10% to 20% of patients with NSCLC have these actionable mutations.25 For the remaining patients, treatment options are limited to platinum‐based cytotoxic chemotherapy, with a response rate ranging between 15% and 30%.26, 27 The recent development of immunotherapy which targets the programmed death‐1/programmed death‐ligand 1 (PD‐L1) axis has been approved for first‐line treatment as well as second‐line treatments of NSCLC in many countries. Here, CD274 is linked to non-small cell lung carcinoma.